July 31, 2023 03:17 PM EDT

Failed trials for 16 IGF-1R inhibitors and $1.6B later: Time for better preclinical models?

Zachary Brennan

Senior Editor

New research published Friday in JAMA Network Open estimates that upwards of $50 billion to $60 billion is spent annually by biopharma companies on failed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Failed trials for 16 IGF-1R inhibitors and $1.6B later: Time for better preclinical models?

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Failed tri­als for 16 IGF-1R in­hibitors and $1.6B lat­er: Time for bet­ter pre­clin­i­cal mod­els?

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Failed trials for 16 IGF-1R inhibitors and $1.6B later: Time for better preclinical models?